1月12日，福瑞医科涨0.32%，截至发稿，报81.50元/股，成交7.76亿元，换手率4.12%，总市值215.96亿 元。福瑞医科股价已经连续4天上涨，区间累计涨幅12.72%。 资料显示，内蒙古福瑞医疗科技股份有限公司位于北京市朝阳区光华东里8号中海广场中楼35层，成立 日期2001年12月26日，上市日期2010年1月20日，公司主营业务涉及从事肝病领域的药品生产与销售、 仪器研发与销售、医疗服务业务。主营业务收入构成为：设备及技术67.57%，药品27.47%，医疗服务 4.30%，其他0.65%。 从基金十大重仓股角度 数据显示，淳厚基金旗下1只基金重仓福瑞医科。淳厚时代优选混合A（014235）三季度持有股数1万 股，占基金净值比例为3.78%，位居第一大重仓股。根据测算，今日浮盈赚取约2600元。连续4天上涨 期间浮盈赚取9.2万元。 淳厚时代优选混合A（014235）成立日期2022年1月27日，最新规模1598.86万。今年以来收益5.29%， 同类排名2356/9012；近一年收益36.62%，同类排名3522/8157；成立以来收益1%。 淳厚时代优选混合A（014235）基金经理为陈 ...

Core Viewpoint - Furuya Co., Ltd. has experienced significant stock price fluctuations and a notable increase in revenue and profit year-to-date, indicating a positive growth trajectory in the medical and pharmaceutical sector [1][2]. Group 1: Stock Performance - On November 4, Furuya's stock price decreased by 2.07%, trading at 72.55 CNY per share, with a total market capitalization of 19.22 billion CNY [1]. - Year-to-date, Furuya's stock price has increased by 130.03%, with a 3.45% rise over the last five trading days, a 4.16% decline over the last 20 days, and a 65.53% increase over the last 60 days [1]. - The company has appeared on the trading leaderboard twice this year, with the most recent instance on September 15, where it recorded a net buy of 74.25 million CNY [1]. Group 2: Financial Performance - For the period from January to September 2025, Furuya achieved a revenue of 1.101 billion CNY, reflecting a year-on-year growth of 12.37%, and a net profit attributable to shareholders of 112 million CNY, up by 9.69% [2]. - Cumulative cash dividends since the A-share listing amount to 246 million CNY, with 52.61 million CNY distributed over the past three years [3]. Group 3: Shareholder Structure - As of September 30, 2025, Furuya had 26,700 shareholders, an increase of 3.24% from the previous period, with an average of 8,742 circulating shares per shareholder, down by 3.09% [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with some shareholders reducing their holdings while new shareholders have entered [3].

Core Viewpoint - Furuya Co., Ltd. has shown significant stock price growth in 2023, with a year-to-date increase of 177.74% and a recent surge of 34.83% over the past five trading days [1] Financial Performance - For the first half of 2025, Furuya Co., Ltd. achieved operating revenue of 713 million yuan, representing a year-on-year growth of 11.02%. However, the net profit attributable to shareholders decreased by 31.09% to 51.93 million yuan [2] - The company has distributed a total of 246 million yuan in dividends since its A-share listing, with 52.61 million yuan distributed over the past three years [3] Stock Market Activity - As of September 17, 2023, Furuya Co., Ltd.'s stock price was 87.60 yuan per share, with a market capitalization of 23.212 billion yuan. The stock experienced a trading volume of 874 million yuan and a turnover rate of 4.34% [1] - The company has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on September 15, 2023, where it recorded a net purchase of 74.25 million yuan [1] Shareholder Information - As of August 29, 2023, Furuya Co., Ltd. had 25,600 shareholders, an increase of 6.91% from the previous period. The average number of circulating shares per shareholder was 9,108, a decrease of 6.47% [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Ruiyuan Growth Value Mixed A, with varying changes in their holdings [3] Business Overview - Furuya Co., Ltd. specializes in the production and sales of pharmaceuticals in the liver disease sector, as well as the research and sales of medical instruments and services. The revenue composition is as follows: 67.57% from equipment and technology, 27.47% from pharmaceuticals, 4.30% from medical services, and 0.65% from other sources [1]